NEW YORK (GenomeWeb News) — Molecular diagnostics developer AdvanDx will use a $15 million blast of Series C financing from BioMérieux and two existing investors to push sales and marketing efforts and to expand its R&D facilities, the company said yesterday.
Joining BioMérieux in the financing is LD Pensions and Scandinavian Life Science Venture.
AdvanDx makes a suite of diagnostics for detecting, identifying, and managing pathogens and infections, including the PNA FISH and Evigene tests, which detect antibiotic-resistant bacteria.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.